caa a22 4500 39759271X CHVBK 20180308164943.0 cr unu---uuuuu 161202e199608 xx s 000 0 eng 10.1093/jac/38.2.215 doi (NATIONALLICENCE)oxford-10.1093/jac/38.2.215 Liposomal amphotericin B (AmBisome) reduces dissemination of infection ad compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis [Elektronische Daten] [A. C. A. P. Leenders, S. de Marie, M. T. ten Kate, I. A. J. M. Bakker-Woudenberg, H. A. Verbrugh] The efficacy of AmBisome, a liposomal formulation of amphotericin B, was compared with that of Fungizone (amphotericin B desoxycholate), in a rat model of unilateral, pulmonary aspergillosis. Repeated administration of cyclophosphamide resulted in persistent, severe, granulocytopenia. The left lung was inwulated with a conidial suspension of Aspergillus fumigatus, thus establishing an unilateral infection. Antifungal treatment was started 40 h after fungal inoculation, at which time mycelial disease was confirmed by histological examination. Both Fungizone 1 mg/kg and AmBisome 10 mg/kg resulted in increased survival in terms of delayed as well as reduced mortality. Quantitative cultures of lung tissue showed that only AmBisome 10 mg/kg resulted in reduction of the number of fungal cfus in the inoculated left lung. Compared with Fungizone, both AmBisome 1 mg/kg/day and AmBisome 10 mg/kg/day significantly prevented dissemination from the infected left lung to the right lung. In addition, both AmBisome regimens reduced hepatosplenic dissemination, and the 10 m/kg dosage fully prevented this complication. In conclusion, when compared with Fungizone, in this model AmBisome is more effective in reducing dissemination of unilateral, pulmonary aspergillosis, even when given in relatively low dosage. Such low dosages may have a place in prophylactic settings. © 1996 by the British Society for Antimicrobial Chemotherapy Original articles nationallicence Leenders A. C. A. P. Department of Bacteriology, University Hospital Rotterdam-Dijkzigt Dr Molewaterplein 40, 3015 GD Rotterdam aut de Marie S. Department of Bacteriology, University Hospital Rotterdam-Dijkzigt Dr Molewaterplein 40, 3015 GD Rotterdam aut ten Kate M. T. Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University Rotterdam P.O. Box 1738, 3000 DR Rotterdam, The Netherlands aut Bakker-Woudenberg I. A. J. M. Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University Rotterdam P.O. Box 1738, 3000 DR Rotterdam, The Netherlands aut Verbrugh H. A. Department of Bacteriology, University Hospital Rotterdam-Dijkzigt Dr Molewaterplein 40, 3015 GD Rotterdam aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/2(1996-08), 215-225 0305-7453 38:2<215 1996 38 jac https://doi.org/10.1093/jac/38.2.215 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.2.215 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Leenders A. C. A. P. Department of Bacteriology, University Hospital Rotterdam-Dijkzigt Dr Molewaterplein 40, 3015 GD Rotterdam aut NATIONALLICENCE 700 1- de Marie S. Department of Bacteriology, University Hospital Rotterdam-Dijkzigt Dr Molewaterplein 40, 3015 GD Rotterdam aut NATIONALLICENCE 700 1- ten Kate M. T. Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University Rotterdam P.O. Box 1738, 3000 DR Rotterdam, The Netherlands aut NATIONALLICENCE 700 1- Bakker-Woudenberg I. A. J. M. Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University Rotterdam P.O. Box 1738, 3000 DR Rotterdam, The Netherlands aut NATIONALLICENCE 700 1- Verbrugh H. A. Department of Bacteriology, University Hospital Rotterdam-Dijkzigt Dr Molewaterplein 40, 3015 GD Rotterdam aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/2(1996-08), 215-225 0305-7453 38:2<215 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford